Wiley Blackwell

SHERPA: Unknown

People

  1. Salles
    Salles
  2. Yahalom
    Yahalom
  3. Imber
    Imber
  4. Palomba
    Palomba
  5. Dogan
    Dogan
  6. Falchi
    Falchi
  7. Kumar
    Kumar
  8. Zelenetz
    Zelenetz
  9. Fregonese
    Fregonese
  10. Horwitz
    Horwitz

Groups

  1. Department of Medicine (30)
  2. Hematologic Malignancies, Division of (30)
  3. Center for Hematologic Malignancies (12)
  4. Lymphoma (11)
  5. Survivorship Research (11)
  6. Hematology-Oncology Fellows (10)
  7. Radiation Oncology, Department of (10)
  8. Graduate Medical Education (9)
  9. Sloan Kettering Institute Postdocs (9)
  10. GME, Radiation Oncology (6)
Search Within
  1. "Gilles Salles"
Formats
  1. Meeting Abstract (25)
  2. Conference Paper (2)
  3. Book Section (1)
  4. Journal Article (1)
  5. Research Letter (1)
Groups
  1. Department of Medicine (30)
  2. Hematologic Malignancies, Division of (30)
  3. Center for Hematologic Malignancies (12)
  4. Lymphoma (11)
  5. Survivorship Research (11)
  6. Hematology-Oncology Fellows (10)

More Groups

People
  1. Gilles Salles (30)
  2. Joachim Yahalom (9)
  3. Brandon Imber (7)
  4. Maria Palomba (6)
  5. Ahmet Dogan (5)
  6. Andrew Zelenetz (5)

More People

Years
  1. 2024 (2)
  2. 2023 (22)
  3. 2021 (6)
Publications
  1. Hematological Oncology (28)
  2. CTS-Clinical and Translational Science (1)
  3. Precision Cancer Therapies: Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice (1)

Results (30)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluation of participation and recruitment bias in a prospective Real World Data in Lymphoma and Survival in Adults (REALYSA) cohort for newly diagnosed lymphoma patients over 1 year in a hematology department of teaching hospital
    Research Letter

    Le Lan, C.; Belot, A.; Golfier, C.; Audin, B.; Sesques, P.; Bernier, A.; Safar, V.; Ferrant, E.; Lazareth, A.; Lequeu, H.; more...
    Hematological Oncology (2024)

    Fulltext@MSK | Save
  • Targeting CD79b in B-cell malignancies
    Book Section

    Owens, C.; Salles, G.; O'Connor, O. A.; Ansell, S. M.; Gribben, J. G.
    In O'Connor, O. A.; Ansell, S. M.; Gribben, J. G. (Eds.) Precision Cancer Therapies: Immunologic Approaches for the Treatment of Lymphoid Malignancies: From Concept to Practice (2024)

    Fulltext@MSK | Save
  • Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX
    Journal Article

    Liao, M. Z.; Deng, R.; Gibiansky, L.; Lu, T.; Agarwal, P.; Dere, R.; Lee, C.; Hirata, J.; Herbaux, C.; Salles, G.; more...
    CTS-Clinical and Translational Science (2023)

    Fulltext@MSK | Save
  • Phase 3 trial of subcutaneous epcoritamab + R‐CHOP versus R‐CHOP in patients (pts) with newly diagnosed diffuse large B‐cell lymphoma (DLBCL): EPCORE DLBCL‐2
    Meeting Abstract

    Sehn, L. H.; Chamuleau, M.; Lenz, G.; Clausen, M. R.; Haioun, C.; Izutsu, K.; Davies, A.; Zhu, J.; Oki, T.; Szafer‐Glusman, E.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Functional precision oncology for follicular lymphoma with patient‐derived xenograft in avian embryos
    Meeting Abstract

    Zala, M.; Lipinski, B.; Costechareyre, C.; Jarrosson, L.; Teinturier, R.; Julia, E.; Verney, A.; Guitton, J.; Traverse‐Glehen, A.; Bachy, E.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignancies
    Meeting Abstract

    Cederquist, G.; Hubbeling, H.; Tringale, K.; Shah, G.; Alarcon Tomas, A.; Shouval, R.; Hajj, C.; Fregonese, B.; Lee, J.; Dahi, P. B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of subcutaneous epcoritamab versus axi‐cel in R/R DLBCL CAR T‐naive and CAR T‐eligible patients: An indirect comparison
    Meeting Abstract

    Thieblemont, C.; Fox, C. P.; Wang, A.; Sail, K.; Alshreef, A.; Moran, M.; Mutebi, A.; Blaedel, J.; Chirikov, V.; Salles, G.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Patient‐ versus clinician‐reported symptoms in the POLARIX study
    Meeting Abstract

    Thompson, C. A.; Mehta‐Shah, N.; Flowers, C.; Salles, G.; Tilly, H.; Chua, N.; Casasnovas, R.; Miall, F.; Kim, T. M.; Tsai, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Five‐year subgroup analysis of tafasitamab + lenalidomide from the phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Dreyling, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save